HEOR, HTA, and Real-World Evidence

Health economics and outcomes research asks how interventions affect outcomes, resource use, costs, value, and decisions in real practice or modeled settings. Health technology assessment places clinical, economic, organizational, ethical, and social evidence into a jurisdictional decision process. Real-world evidence uses data collected outside conventional controlled-trial contexts to answer defined questions.

Decision context controls the document

Before drafting, define the decision-maker, population, intervention, comparators, perspective, jurisdiction, time horizon, outcome measures, evidence sources, model type, willingness-to-pay or decision framework where relevant, and submission instructions. A globally persuasive value story may still fail if it does not answer a local payer's specified question.

Economic evaluations

Report the type of evaluation and its analytical perspective. Explain comparators, time horizon, discounting, outcomes, resource use, cost sources and price year, currency and conversions, model structure, assumptions, input selection, extrapolation, uncertainty, validation, heterogeneity, distributional considerations where applicable, and limitations.

Keep the base case distinct from scenarios and sensitivity analyses. Show which conclusions depend on uncertain assumptions. A model is an explicit representation of a decision problem, not observed reality. Avoid giving projected values the rhetorical status of measured facts.

Budget-impact work

Budget-impact analysis focuses on affordability and financial consequences for a defined payer or system over a defined period. Describe eligible population, uptake, displacement, treatment duration, resource consequences, costs, scenarios, and uncertainty. Keep clinical value and short-term budget effect conceptually distinct.

Real-world data and evidence

Define the data source, provenance, collection purpose, linkage, population coverage, observation period, coding, completeness, validation, and fitness for use. Make cohort construction reproducible. Explain exposure, outcome, confounder, and covariate algorithms; index dates and windows; handling of duplicates and missingness; and bias-control methods.

Common risks include immortal-time bias, confounding by indication, selection bias, outcome misclassification, incomplete capture, data drift, inconsistent coding, and causal language unsupported by design. Report sensitivity analyses and negative or alternative controls when part of the method, and state residual uncertainty plainly.

HTA and payer submissions

Follow the current jurisdictional methods and submission template. These may govern comparator, evidence hierarchy, indirect comparison, economic model, population subgroup, uncertainty, dossier format, stakeholder input, and procedural timing. Use a requirement matrix to connect every requested item to the evidence and document location.

Clinical, economic, and patient evidence should form one decision narrative without being blended into one kind of claim. Patient-reported outcomes and preference evidence need their own methods, instruments, interpretation thresholds, and limitations.

HEOR quality card

Check that the decision problem, population, comparators, perspective, horizon, data sources, model, assumptions, inputs, costs, outcomes, uncertainty, validation, and limitations are transparent. Every number should be classifiable as observed, derived, assumed, modeled, or sourced from literature. Reconcile narrative claims with evidence tables, model outputs, and the submitted base case.